AaviGen

Executive Summary

AaviGen is a privately held German biotechnology company founded in 2018 and headquartered in Munich, dedicated to developing novel gene therapies for cardiac diseases, particularly heart failure. The company leverages its proprietary platform to engineer heart-specific Adeno-Associated Viral (AAV) vectors that enable safe, precise, and minimally invasive administration. By targeting the root molecular causes of cardiac conditions, AaviGen aims to offer patient-tailored therapies that address the high unmet need in heart failure, a leading cause of morbidity and mortality worldwide. The company's technology differentiates through improved cardiac tropism and reduced off-target effects, potentially overcoming key limitations of conventional AAV vectors. While AaviGen is still in a preclinical stage, its focused approach and experienced team position it as a promising player in the gene therapy landscape.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026IND Filing for Lead Cardiac Gene Therapy Candidate60% success
• H1 2027Strategic Partnership with Cardiovascular Biotech or Pharma50% success